

NEWS

DEAL

REPORT

Hengeler Mueller advises Evonik on sale of AlzChem Group

Evonik Industries AG, a global leader in speciality chemicals, has finalised the sale of the AlzChem Group to the Luxembourg-based private equity fund BluO. The transaction covers the entire AlzChem Group and its companies in Germany and the US. After approval by the boards and relevant antitrust authorities, the deal was closed on October 27, 2009. The cash sale price (excluding assumed liabilities) amounts to € 78.5 million.

Hengeler Mueller advised Evonik Industries AG on this transaction. The Hengeler Mueller team included partner Daniel Wiegand (M&A) as well as associates Matthias Lack and Marc Zedler (all Munich).

Responsible for this transaction within Evonik's in-house legal department was Melanie J. Flessner (Head of M&A).

Partner and Press Contacts

Dr. Daniel Wiegand

- Partner -

Hengeler Mueller

Partnerschaft von Rechtsanwälten

Leopoldstrasse 8-10

80802 Munich

Tel.: +49 89 383388-406

Fax: +49 89 383388-7416

daniel.wiegand@hengeler.com

Keith D. Bain

- PR Manager -

Hengeler Mueller

Partnerschaft von Rechtsanwälten

Bockenheimer Landstrasse 24

60323 Frankfurt

Tel.: +49 69 17095-207

Fax: +49 69 725773

keith.bain@hengeler.com

30 October 2009

HENGELER MUELLER

www.hengeler.com